Key Highlights

● Third-quarter revenue was about $2.34 million, up roughly 19%.

● The company paid a special cash dividend of $0.075 per share.

● Cash was about $1.52 million and marketable securities $7.06 million.

● Average daily trading volume was only 862 shares.

When a very small, thinly traded company pays a special dividend and holds most of its assets in cash and Treasuries, the balance sheet becomes the story. Pharma-Bio Serv (OTC:PBSV), a consulting firm serving pharmaceutical and biotech manufacturers, fits that description. Its fiscal third-quarter revenue rose and its losses narrowed, according to a research note published in September. Investors may be weighing an improving operating trend against the limits of a company with tiny trading volume.

Latest Company Context

According to a small-cap research report dated September 15, 2026, revenue for the quarter ended July 31, 2026 was about $2.34 million, up roughly 19% from $1.96 million. Nine-month revenue was about $7.33 million, up roughly 7%. Nine-month net income was about $252,000, or about $0.011 per diluted share, compared with a net loss of about $100,000 a year earlier. The third-quarter net loss narrowed to about $14,000 from about $204,000. Gross margin edged up to 29.6% from 29.2%, and selling, general and administrative expense fell to about $764,000 from $888,000, mainly on lower occupancy costs.

The report disclosed that its publisher was compensated by the issuer for non-investment-banking services, so its tone should be read with that in mind. The quarterly figures remain very small in absolute terms. A revenue increase of roughly $380,000 from the prior-year quarter accounts for the 19% growth, so modest changes in a handful of engagements can move percentages noticeably. Investors may therefore want to look at multi-quarter trends rather than a single period.

Key Business and Index Drivers

The company provides regulatory compliance, quality assurance, validation, technology transfer, engineering and project management services, mainly in Puerto Rico, the continental United States and Europe, with a smaller presence in Brazil. Revenue grew in all three main regions in the quarter. The balance sheet showed about $1.52 million in cash and $7.06 million in marketable securities, mostly short-term U.S. Treasuries, against total liabilities of about $1.0 million. The company paid a special cash dividend of $0.075 per share, about $1.72 million, earlier in 2026, and the annual dividend was listed at $0.08.

The report quoted a 16.7% yield that does not match the stated figures, so that yield is not relied upon. The stock trades on the OTCQB, and no index membership applies. Because the company holds roughly $8.6 million in cash and securities against a market capitalisation near $12 million, a large share of its stated value is liquid, which is a feature investors may weigh alongside its small operating scale.

What Investors Should Watch

Investors may watch whether revenue growth continues and whether the company moves from small quarterly losses to consistent profit. Dividend policy is another focus, since the special payout was sizeable relative to the company's cash and securities. Liquidity in the shares is limited: the report cited average daily volume of only 862 shares, a market capitalisation near $12 million and a 52-week range of $0.42 to $0.69, so prices may move on small trades and may not be a reliable indicator of value. Institutional ownership was listed at 0% and insider ownership at 13%. The report's valuation estimate is an analyst opinion, not a forecast guaranteed to hold. The company's reliance on pharmaceutical manufacturing activity in Puerto Rico and the continental United States ties its fortunes to that industry's spending on compliance and validation.

Cash Counts More Than Quarterly Noise

Pharma-Bio Serv shows signs of operating improvement alongside a conservative balance sheet, but its small scale and thin trading limit how much weight any single data point can carry. The confirmed facts are the revenue and earnings trends reported; the interpretation of valuation is subjective. Further quarterly filings may show whether the improvement is sustained.